Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Understanding Cancer and Treatment for a Better World
- Cancer Congress 2018

About Conference

Allied Academies welcomes you to attend “Global Congress on Cancer Science and Therapy” held in the beautiful city of  Madrid, Spain on August 23 - 24 with the theme “Understanding cancer and treatment for a better world”. We amiably invite you to attend the conference and share your research on Cancer Science and Therapy. Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. 
Target audience:
  • Chiefs/Managers and Business Delegates
  • Founders
  • Director of Laboratories
  • Universities
  • Industries
  • Investigators
  • Post-Doctoral Fellows
  • Research and Diagnostic Laboratories
  • Clinical Fellows
  • Research Scholars
  • Students
  • Technology Experts
  • Biomedical Research organizations
  • Medical oncologists
  • Surgical oncologists
  • Radiotherapists
  • Pathologists

Welcome Message

Allied Academies cordially welcomes all the participants and contributors from worldwide to attend the Conference .It is to spread knowledge, awareness,and education about the recent advances in the treatment of cancer and development of a new treatment to reduce the death rate because of cancer and to develop painless treatment of cancer. With people from around the world focused on getting some answers concerning Cancer Science and Therapy,this is your single most obvious opportunity to accomplish the greatest accumulation of individuals from the mending focuses, Universities, bunch,etc.  

Scientific Sessions

Session 1: Cell Death Mechanisms to Novel Cancer Treatments

Despite remarkable progress in the discovery and development of novel cancer therapeuticscancer remains the second leading cause of death in the world. For many years, compounds derived from plants have been at the forefront as an important source of anticancer therapies and have played a vital role in the prevention and treatment of cancer because of their availability, and relatively low toxicity when compared with chemotherapy. More than 3000 plant species have been reported to treat cancer and about thirty plant-derived compounds have been isolated so far and have been tested in cancer clinical trials. The mechanisms of action of plant-derived anticancer drugs are numerous and most of them induce apoptotic cell death that may be intrinsic or extrinsic, and caspase and/or p53-dependent or independent mechanisms. Alternative modes of cell death by plant-derived anticancer drugs are emerging and include mainly autophagy, necrosis-like programmed cell death, mitotic catastrophe, and senescence leading to cell death. Considering that the non-apoptotic cell death mechanisms of plant-derived anticancer drugs are less reviewed than the apoptotic ones, this paper attempts to focus on such alternative cell death pathways for some representative anticancer plant natural compounds in clinical development. In particular, emphasis will be on some promising polyphenolics such as resveratrol, curcumin, and genistein; alkaloids namely berberine, noscapine, and colchicine; terpenoids such as parthenolide, triptolide, and betulinic acid; and the organosulfur compound sulforaphane. The understanding of non-apoptotic cell death mechanisms induced by these drugs would provide insights into the possibility of exploiting novel molecular pathways and targets of plant-derived compounds for future cancer therapeutics.
  • Mechanisms and regulation of classical apoptotic and non-classical modes of cell death.
  • Mechanistic insight into autophagy and senescence 
  • Therapeutic strategies modulating cell death in cancer cells


Session 2: Basic Science to Clinical Trials

The effective management of malignant melanoma has remained centred around the surgeon. The arrival of anti-angiogenic agents as the ‘fourth’ cancer treatment joining the ranks of surgery, chemotherapy and radiotherapy has been a source of renewed hope. This provides an up-to-date review of the focus, state and rationale of clinical trials of anti-angiogenic therapies in metastatic malignant melanoma. Vascular Endothelial Growth Factor (VEGF) is by no means the only target, although perhaps the most extensively studied following the successful introduction of the anti-VEGF Antibody bevacizumab. This has been combined with other established therapies to try and improve outcomes in metastatic disease, and is being trialled in the UK to prevent metastasis in high-risk patients. We describe the encouraging preclinical work that lead to great enthusiasm for these agents, assess the key trials and their outcomes. 

·          Embryonic stem cells

·          Immunomodulation

·          Therapeutic target in cancer

·          Drug development


Session 3: Molecular Pathology Approach to Cancer

Molecular pathology is one of the linchpins of precision medicineNo longer can treatment decisions related to therapy selection be rendered solely on the basis of histopathological analyses, as genomic analyses of human cancers are resulting in the identification of the genetic determinants of  tumourigenesis, cancer progression and therapy response.

Session 4: Mechanisms to therapies

Several scientific and clinical studies have shown an association between chronic alcohol consumption and the occurrence of cancer in humans. The mechanism for alcohol-induced carcinogenesis has not been fully understood, although possible events include genotoxic effects of acetaldehyde, cytochrome P450 2E1 (CYP2E1)-mediated generation of reactive oxygen species, aberrant metabolism of folate and retinoids, increased estrogen, and genetic polymorphisms. The impact of alcohol drinking on the risk of cancer development and potential underlying molecular mechanisms. The interactions between alcohol abuse, anti-tumor immune response, tumor growth, and metastasis are complex. However, multiple studies have linked the immunosuppressive effects of alcohol with tumor progression and metastasis. The influence of alcohol on the host immune system and the development of possible effective immunotherapy for cancer in alcoholics are also discussed. The conclusive biological effects of alcohol on tumor progression and malignancy have not been investigated extensively using an animal model that mimics the human disease. The review provides insights into cancer pathogenesis in alcoholics, alcohol and immune interactions in different cancers, and scope and future of targeted immunotherapeutic modalities in patients with alcohol abuse.

Session 5: Cancer Precision Medicine

Through the precision medicine approach, the treatment of each patient can be focused on drugs most likely to benefit him or her, sparing the patient the cost and potential harmful side effects from drugs that are unlikely to be beneficial. For example, drugs targeted to the HER2 protein are offered only to the 20 percent of breast cancer patients who have disease that tests positive for high levels of HER2.

  • Trials in Low survival rate cancers
  • Cellular stress
  • Nanomedicine
  • Emerging techniques in biomarker discovery drug development and patient stratification


Session 6: Immunotherapy of Cancer

Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight the cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work in these ways.

  • Stopping or slowing the growth of cancer cells
  • Stopping cancer from spreading to other parts of the body
  •  Helping the immune system work better at destroying cancer cells

There are several types of immunotherapy, including:

  •  Monoclonal antibodies
  • Non-specific immunotherapies
  • Oncolytic virus therapy
  • T-cell therapy
  • Cancer vaccines

Session7: Signalling Pathways in Cancer

Cancer is driven by genetic and epigenetic alterations that allow cells to over proliferate and escape mechanisms that normally control their survival and migration. Many of these alterations map to signaling pathways that control cell growth and division, cell death, cell fate, and cell motility, and can be placed in the context of distortions of wider signaling networks that fuel cancer progression, such as changes in the tumor microenvironment, angiogenesis, and inflammation. Mutations that convert cellular proto-oncogenes to oncogenes can cause hyper activation of these signaling pathways, whereas inactivation of tumor suppressors eliminates critical negative regulators of signaling. An examination of the PI3K-Akt and Ras-ERK pathways illustrates how such alterations dysregulate signaling in cancer and produces many of the characteristic features of tumor cells.

Session 8: Modes of Cancer Spread

Metastasis is a pathogenic agent's spread from an initial or primary site to a different or secondary site within the host's body; it is typically spoken of as such spread by a cancerous tumor. The newly pathological sites, then, are metastases (mets). Cancer occurs after cells are genetically altered to proliferate rapidly and indefinitely. This uncontrolled proliferation by mitosis produces a primary heterogeneic tumour. The cells which constitute the tumor eventually undergo metaplasia, followed by anaplasia then dysplasia, resulting in a malignant phenotype. This malignancy allows for invasion into the circulation, followed by invasion to a second site for tumorigenesis.

Session 9: Familial Cancer 

Cancer that occurs in families more often than would be expected by chance. These cancers often occur at an early age, and may indicate the presence of a gene mutation that increases the risk of cancer. They may also be a sign of shared environmental or lifestyle factors.

Session 10: Economic Impact on Cancer

Distribution in economics refers to the way total output, income, or wealth is distributed among individuals or among the factors of production (such as labour, land, and capital). In general theory and the national income and product accounts, each unit of output corresponds to a unit of income. Cancer can be a major cause of lack of money. This may be due either to the costs of treating and managing the illness as well as its impact upon people's ability to work. This particularly affects countries that lack comprehensive social health insurance systems and other types of social safety nets. The study is a longitudinal short study of 10,000 hospital patients with a first time diagnosis of cancer. Patients were assigned a socioeconomic status according to the district of residence at diagnosis. Continuity of patients due to cancer living in the most deprived district was compared to survival of patients living in all other districts by model-based period analysis. These major regional socioeconomic inequalities indicate a potential for improving cancer care and survival in Germany. Studies on individual patient data with access to cancer treatment information should be conducted to examine the reasons for these socioeconomic inequalities in cancer survival.

Session 11: Cancer and Alternative Medicine

 Ayush system is the most common term used for the cancer treatmentAyurvedic medicine is an ancient Indian system of medicine which began about 5,000 years ago. It is not just one treatment. It is a way of diagnosing illness and using a wide range of treatments and techniques. Herbal medicine uses plants, or mixtures of plant extracts, to treat illness and promote health. It aims to restore your body's ability to protect, regulate and heal itself. It is a whole body approach, so looks at your physical, mental and emotional wellbeing. It is sometimes called phytomedicine, phytotherapy or botanical medicine. Naturopathic doctors (NDs) believe that cancer arises from an imbalance that causes a systemic breakdown within the body. Homeopathy is based on the theory of treating like with like. So to treat an illness a homeopathic therapist (homeopath) uses tiny doses of a substance that in large doses would actually cause the symptoms of the illness.

 

Session 12: Cancer Biomarkers

Protein Biomarkers can be used as biomarkers for early detection of cancers especially used for the identification of breast cancer. Diagnostic Patients with suspected pancreatic cancer will undergo an initial CT scan to determine if a suspect mass is localized and removed by surgery 63% of patients will be diagnosed with non-resectable stage III and IV disease and a biopsy will be undertaken to confirm pancreatic cancer by H&E pathological analysis.  The presence of cancerous cells via pathology is very challenging due to high numbers of non-cancerous stromal infiltrating cells and administration of chemotherapy or enrolment into a clinical trial will only commence on definitive diagnosis of pancreatic cancer. These will notice specifically stains neoplastic pancreatic cells would enable the pathologist to confidently diagnose pancreatic cancer and thus offer appropriate cancer treatment to the patients. The Novel Biomarker BI-010 has been identified as a highly sensitive (98%) and specific (95%) IHC marker for pancreatic cancer and CRT is seeking a partner to develop an IHC based test to detect BI-010 in fine needle aspirate biopsies from biopsy samples.

Session 13: Diagnostics and Staging

X-radiation (composed of X-rays) is a form of electromagnetic radiation Magnetic resonance imaging (MRI) is a type of scan that uses strong magnetic fields and radio waves to produce detailed images of the inside of the body. An ultrasound scan, sometimes called a sonogram, is a procedure that uses high-frequency sound waves to create an image of part of the inside of the body. A biopsy is a medical test commonly performed by a surgeon, interventional radiologist, or an interventional cardiologist involving sampling of cells or tissues for examination. A complete blood count (CBC) gives important information about the kinds and numbers of cells in the blood, especially red blood cells, white blood cells, and platelets. Cancer staging is the process of determining the extent to which a cancer has developed by spreading. The TNM Classification of Malignant Tumours (TNM) is a cancer staging notation system that gives codes to describe the stage of a person's cancer, when this originates with a solid tumour. Pathologic staging, where a pathologist examines sections of tissue, can be particularly problematic for two specific reasons: visual discretion and random sampling of tissue.

Session 14: Radiation oncology

Radiation oncology is one of the three primary specialties, the other two being surgical and medical oncology, involved in the treatment of cancerA Radiation Oncologist is a specialist physician who uses ionizing radiation (such as megavoltage X-rays or radionuclides) in the treatment of cancer. Brachytherapy is an advanced cancer treatment. Radioactive seeds or sources are placed in or near the tumour itself, giving a high radiation dose to the tumour while reducing the radiation exposure in the surrounding healthy tissues. External beam therapy (EBT), also called external radiation therapy, is a method for delivering a beam or several beams of high-energy x-rays to a patient's tumourIntraoperative radiation therapy or IORT is the application of therapeutic levels of radiation to the tumour bed while the area is exposed during surgery. Systemic radiation therapy is a type of radiation therapy in which radioactive material travels through the bloodstream to reach cells all over the body. Systemic radiation is used to treat certain types of cancer, such as thyroid cancer, or to relieve pain when cancer has spread (metastasized) to the bone. Radio immunotherapy (RIT) uses an antibody labelled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumour-associated antigen is used to deliver a lethal dose of radiation to the tumour cells to relieve pain when cancer has spread (metastasized) to the bone. Radio immunotherapy (RIT) uses an antibody labelled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumour-associated antigen is used to deliver a lethal dose of radiation to the tumour cells.

Session 15: Chemotherapy

Chemotherapeutic agent an agent used to treat cancer administered in regimens of one or more cycles, combining two or more agents over a period of days to weeks. Intravenous chemotherapy is one way to receive cancer-fighting medicine. Oral chemotherapy (chemo) is a treatment used to shrink a tumour or kill cancer cells. Oral chemo is usually taken in the form of a pill or capsule. Arterial chemotherapy infusion of the liver and chemoembolization of the liver (transarterial chemoembolization or TACE) are similar procedures that are used for the treatment of cancers in the liver. Adjuvant therapy or care, also called adjunct therapy or adjunctive therapy or care, is therapy that is given in addition to the primary, main, or initial therapy to maximize its effectiveness. Topical chemotherapy is a cream or lotion applied directly to the skin cancer. Different drugs cause different side effects. Certain types of chemotherapy often have specific side effects. But, each person’s experience is different.

Market Analysis

The global cancer diagnostics market was valued at USD 101.0 billion in 2013 and is expected to grow at a CAGR of 7.6% from 2014 to 2020, to reach an estimated value of USD 168.6 billion in 2020. The global cancer biomarkers market is expected to reach USD 15,973.8 Million by 2020, at a CAGR of 11.6% from 2015 to 2020. In 2010, the global cancer market was valued at $54 billion, with forecasted Compound Annual Growth Rate (CAGR) growth to $81 billion by 2016. The seven major cancer markets (US, France, Germany, Italy, Spain, United Kingdom and Japan) represented ~79% of the 2010 global cancer market ($43 billion). The US dominated 2010 sales with a market share of 38.5% and the leading ten companies of the global cancer  market represented 87.1% ($47 billion) of the total market.




Why Spain?

Spain, a country on Europe’s Iberian Peninsula, includes 17 autonomous regions with diverse geography and cultures. Capital city Madrid is home to the Royal Palace and Prado museum, housing works by European masters. Segovia has a medieval castle and an intact Roman aqueduct. Catalonia’s capital, Barcelona, is defined by Antoni Gaudí’s whimsical modernist landmarks like the Sagrada Família church.


Societies and Universities Associated with oncology and cancer research:

Worldwide Societies (International):

 

1. Society of Oncology and Cancer Research of Nigeria (SOCRON)

2. European society for medical oncology

3. American Society of Clinical Oncology

4. Swiss Group for Clinical Cancer Research

5. American Institute for Cancer Research (AICR)

6. National Foundation for Cancer Research

7. Cancer Research Institute

8. Institute of Cancer Research, London

9. European Academy of Tumor Immunology (EATI)

10. American Association for Cancer Research (AACR)

11. National Cancer Institute

12. Cancer Research UK

13. Memorial Sloan Kettering Cancer Center

14. Ludwig Institute for Cancer Research

15. National Institutes of Health (NIH)

16. Breast Cancer Research Foundation

17. Amgen

18. University of Texas MD Anderson Cancer Center

19. World Cancer Research Fund International

20. AstraZeneca

21. Sage Bionetworks

22. Dana–Farber Cancer Institute

23. Genentech, Inc

24. Prevent Cancer Foundation

25. Netherlands Cancer Institute

26. Walker Cancer Research Institute

27. University of California, San Francisco

28. Broad Institute of MIT and Harvard

29. National Cancer Centre Singapore

30. International Agency for Research on Cancer


Industries Associated with oncology and cancer research:


1. Roche

2. Celgene Corporation

3. Johnson & Johnson

4. Pfizer Inc.

5. Bristol-Myers Squibb

6. Novartis

7. Merck & Co., Inc.

8. AstraZenecav

9. AbbVie

10. Eli Lilly

To Collaborate Scientific Professionals around the World

Conference Date August 23-24, 2018
Speaker Oppurtunity Day 1 Day 2
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Sponsorship Opportunities Click here for Sponsorship Opportunities
Venue
&
Hospitality


Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Program enquiry
cancercongress@alliedsummit.org
Sponsorship opportunity
cancersummit@alliedannualsummit.com
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.

Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contact cancercongress@alliedsummit.org to request for a personalized letter of invitation, if not received until one month before the scheduled date of event.

All the bank charges applicable during refund will be deducted from the account of participant.

Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

If, due to any reason, Allied academies postpone an event on the scheduled date, the participant is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to finance@alliedacademies.com. Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa. 

Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy Orders are available:

  • Before 60 days of the conference: Eligible for Full Refund after deduction of $100 towards service Fee.
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

Copyright © 2018-2019 Allied Academies, All Rights Reserved.